You are here: Industry Insights > multiple myeloma

News List

Potential new CAR-T cell therapy for multiple myeloma firstwordpharma
June 28, 2021
Researchers at Mayo Clinic Cancer Center are studying a potential new chimeric antigen receptor-T cell therapy (CAR-T cell therapy) treatment for multiple myeloma. Their findings were published on Friday, June 24, in The Lancet.
Innovent Biologics and IASO Biotherapeutics to Present Updated Data from its Anti-BCMA CAR-T Therapy in Relapsed/Refractory Multiple Myeloma at European Hematology Association (EHA) Congress prnasia
June 08, 2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, together with IASO Biotherapeutics ...
Clinical Trial Results of the BCMA CAR-T Co-developed by Innovent and IASO Biotherapeutics Commented in American Society of Hematology's Medical Journal "Blood" prnasia
June 03, 2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, together with IASO Biotherapeutics ...
Talquetamab shows promise in multi-drug refractory multiple myeloma patients europeanpharmaceuticalreview
May 27, 2021
New Phase I data shows 65 percent of triple-class and 83 percent of penta-drug refractory multiple myeloma patients responded to talquetamab.
Janssen seeks EU approval for first CAR-T therapy cilta-cel pharmatimes
May 07, 2021
Johnson & Johnson’s (J&J) pharma division Janssen has filed its first CAR-T cell therapy ciltacabtagene autoleucel (cilta-cel) with the European Medicines Agency (EMA), seeking approval for the treatment of patients with relapsed/refractory multiple ...
EC approves new Sarclisa indication pharmatimes
April 20, 2021
The European Commission has approved Sanofi’s Sarclisa in combination with standard of care regimen carfilzomib and dexamethasone (Kd) for the treatment of relapsed multiple myeloma.
Menarini Silicon Biosystems launches CELLSEARCH® Circulating Multiple Myeloma Cells Assay, a new non-invasive test to monitor disease status in clinical research studies prnasia
April 02, 2021
Menarini Silicon Biosystems, a pioneer of liquid biopsy and single cell technologies, announced the launch of a new assay to meet the needs of pharma companies, CROs, clinicians and research scientists working on multiple myeloma (MM).
FDA green light for Sarclisa combo in multiple myeloma pharmatimes
April 01, 2021
French pharma company Sanofi has received US Food and Drug Administration (FDA) approval for its CD38 inhibitor Sarclisa in combination with carfilzomib and dexamethasone (Kd) for the treatment of advanced multiple myeloma.
Ide-cel provides lasting remissions in multiply-relapsed myeloma europeanpharmaceuticalreview
February 26, 2021
BMS and bluebird bio have applied to the FDA for approval of ide-cel as a standard therapy for relapsed or refractory multiple myeloma based on positive Phase II trial results.
Cartesian Initiates Phase 2 Clinical Trial of RNA-Engineered Cell Therapy for Frontline Cancer americanpharmaceuticalreview
February 26, 2021
Cartesian Therapeutics has initiated a Phase 2a clinical trial of its mRNA chimeric antigen receptor (CAR) T-cell therapy, Descartes-11, in patients with newly diagnosed, high-risk multiple myeloma.

Previous page 1 2 3 4 5 6 7 8 9 Next page